Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

Johannesen, Camilla Ditlev Lindhardt, Mortensen, Martin Bødtker, Langsted, Anne, Nordestgaard, Børge Grønne·2021·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2021.01.027

Cited by (355)

Items 301–355 of 355

  1. Additional file 3 of Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease
    Xing Shui, Zheqi Wen, Dong, Ruimin, Chen, Zefeng, Tang, Leile, Wenyu Tang, Wu, Zhen, Chen, Lin · 2023 · Figshare
  2. Additional file 1 of Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study
    Huh, Ji Hye, Han, Kyung-do, Yun Kyung Cho, Eun Roh, Jun Goo Kang, Seong Jin Lee, Ihm, Sung-Hee · 2022 · Figshare
  3. Additional file 1 of Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease
    Xing Shui, Zheqi Wen, Dong, Ruimin, Chen, Zefeng, Tang, Leile, Wenyu Tang, Wu, Zhen, Chen, Lin · 2023 · Figshare
  4. Additional file 1 of Cumulative exposure to AHA Life's Essential 8 is associated with nonalcoholic fatty liver disease: a large cohort study
    Yaqin, Wang, Shuwen, Deng, Ting, Yuan, Xiaoling, Zhu, Yuling, Deng, Lei, Liu, Changfa, Wang · 2024 · Figshare
  5. Additional file 1 of Cumulative residual cholesterol predicts the risk of cardiovascular disease in the general population aged 45 years and older
    Zhao, Mengjie, Xiao, Mengli, Tan, Qin, Ji, Jinjin, Lu, Fang · 2024 · Figshare
  6. Additional file 1 of Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study
    Massimiliano Ruscica, Chiara Macchi, Angelica Giuliani, Alessandra Stefania Rizzuto, Deborah Ramini, Matilde Sbriscia, Carugo, Stefano, Bonfigli, Anna Rita, Alberto Corsini, Fabiola Olivieri et al. · 2023 · Figshare
  7. Additional file 2 of The chain-mediating effect of Crp, BMI on the relationship between dietary intake of live microbes and hyperlipidaemia
    Chen, Jingyi, Fang, Shuhua, Jinlin Huo, Nian Yang · 2024 · Figshare
  8. Additional file 1 of Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study
    Huang, Ying, Chen, Siwei, Huachun Pan, Shumin Yang, Cheng, Wenke · 2024 · Figshare
  9. Genome-wide association study for residualized-apolipoprotein B elucidates the role of apolipoprotein B in coronary artery disease risk
    Selena K. Zhang, Satoshi Koyama, Tiffany R. Bellomo, Sara Haidermota, Whitney Hornsby, Michael C. Honigberg, Patrick T. Ellinor, Pradeep Natarajan · 2025 · medRxiv
  10. Impact of the implementation of the Sampson-NIH equation for the calculation of LDL-C in a large community cohort of adult and pediatric patients in Ontario
    Nicole White-Al Habeeb, Terence Agbor, Difei Sun, Adam Wan, Michelle Seaton, Peter Catomeris, Danijela Konforte · 2025 · Clinical Biochemistry
  11. Combined Impact of Mean and Variability of Non-HDL Cholesterol on Myocardial Infarction in Hemodialysis Patients
    Hanbi Lee, Ji Won Min, Tae Hyun Ban, Eun Sil Koh, Hye Eun Yoon, Young Soo Kim, Hyung Wook Kim, Byung Ha Chung · 2025 · Journal of Clinical Medicine
  12. Alterations in cardiometabolic markers associated with Canada-wide and sector-specific multiple air pollutant exposures
    Jessica Evans, Robert Dales, Kimberly Mitchell, Sabit Cakmak · 2026 · Environmental Pollution
  13. From LDL to apolipoprotein B: shifting the lens on cardiovascular risk
    Sterenn Guillerme, Jean-François Perregaux, Antonio Gallo · 2026 · European Journal of Preventive Cardiology
  14. Attainment of non-high-density lipoprotein cholesterol targets in secondary and primary care: A secondary-analysis of the DA VINCI study
    Aksaan Arif, Irene Karungi, Christophe A. T. Stevens, Amany K. Elshorbagy, Kausik Kumar Ray · 2026 · Atherosclerosis
  15. Wash-Free and Simultaneous Imaging Assay of PCSK9 and ApoB Proteins for Efficient Screening and Efficacy Evaluation of the PCSK9 Inhibitors
    Ruyu Yang, Xinmei Liu, Xinning Gai, Jianing Song, Jialing Li, Ping Li, Chen Zong · 2026 · Analytical Chemistry
  16. Changes in apolipoproteins following ingestion of a beverage delivering β-hydroxybutyrate: results from a randomized placebo-controlled trial
    Yutong Liu, Wandia Kimita, Sakina H. Bharmal, Maxim S. Petrov · 2026 · Frontiers in Nutrition
  17. Long-term prognostic value of apolipoprotein B levels in patients with very premature (≤40 years) acute coronary syndrome
    Lοukianos S. Rallidis, Sofia‐Panagiota Giannakopoulou, Stylianos Armylagos, Christos Kotakos, Stylianos L. Rallidis, Eleni P Stathopoulou, Demosthenes B. Panagiotakos · 2026 · Journal of clinical lipidology
  18. Lifestyle characteristics and plasma biomarkers for risk of MASLD differ by sex in the general population
    Lærke Kristine Kyhl, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen, Michael Huy Cuong Pham, Jørgen Tobias Kühl, Klaus Fuglsang Kofoed, S. Pors Nielsen · 2026 · European Journal of Internal Medicine
  19. Modern Approaches to Dyslipidemia: Integrating Advanced Risk Markers and Imaging in Primary Care
    Humza Siddiqi, Mahvash Husain · 2026 · Texas Family Medicine Research Journal
  20. Five lipid-inflammation composite indices and obesity-related metabolic disorders, cardiovascular and renal diseases A multi-state trajectory analysis using data from the UK Biobank cohort
    Ran He, Qikai Luo, Taian Jin, Qi Liu, Yiwei Shang, Zihan Fang, Juan Jin, Qiang He · 2026 · Diabetes Research and Clinical Practice
  21. Influencing factors and predictive model construction of perioperative blood glucose fluctuations in patients with coronary heart disease complicated with type 2 diabetes mellitus undergoing percutaneous coronary intervention
    Xuemei Zhao, Yi Wen, Mingxia Zheng · 2026 · BMC Endocrine Disorders
  22. Beyond LDL-C Targets: The Value of Cholesterol Ratios in Unmasking Residual Risk
    Kwang‐Il Kim · 2026 · Korean Circulation Journal
  23. Small Dense Low-Density Lipoprotein Cholesterol Predicts Long-Term Coronary Artery Disease Recurrence in Patients Without Metabolic Dyslipidemia
    Shinji Koba, Yuya Yokota, Noriyuki Satoh, Yasuki Ito, Fumiyoshi Tsunoda, Koshiro Sakai, Yuya Nakamura, Makoto Shoji, Tsutomu Hirano, Toshiro Shinke · 2026 · Circulation Journal
  24. Inflammation and lipid-related determinants in coronary atherosclerosis: mechanisms, biomarkers, and therapeutic implications
    Fubo Zhang, Qingchi Liao · 2026 · Frontiers in Cardiovascular Medicine
  25. Apolipoprotein B/A1 Ratio for Predicting Major Adverse Cardiovascular Events in Coronary Artery Disease: Development and Validation of a Nomogram
    Hongxu Zhu, Qi Jin · 2026 · International Journal of General Medicine
  26. Lipid-related cardiovascular risk beyond low-density lipoprotein cholesterol
    Mie Balling, Karen Hvid, Anette Varbo, Anne Langsted, Børge Grønne Nordestgaard, Shoaib Afzal · 2026 · Heart
  27. Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets – a SwissDiab study
    Christina Liu, Frida Renström, Giacomo Gastaldi, Michael Brändle, Stefan Bilz · 2026 · Frontiers in Endocrinology
  28. Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins
    Vikrama Raja, C A Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein ElBadawi, Michel Farnier, Kumari Pushpa, Lale S Tokgözoğlu, Alberto Zambon, Jean‐Pascal Berrou et al. · 2026 · Frontiers in Cardiovascular Medicine
  29. Standardization Challenges and Breakthroughs in Apolipoprotein B Detection: From Immunoassays to LC‐MS/MS
    Anqi Pan, Haijian Zhao, Jing Wang, Jiangtao Zhang, Hao Zheng, C J Zhang, Wenxiang Chen, Tianjiao Zhang · 2026 · Mass Spectrometry Reviews
  30. Excess apolipoprotein B improves risk assessment of all-cause and cardiovascular mortality in patients with aortic stenosis: insights from the ARISTOTLE study
    M Xie, Zhenyu Xiong, Zhen Guo, R Li, Shaozhao Zhang, Guanzhong Chen, Lixiang He, Wei Zhang, Menghui Liu, J Y Li et al. · 2026 · European journal of medical research
  31. Lower LDL-c/ApoB ratio is associated with adverse cardiovascular outcomes and advanced peripheral artery disease
    Sanjiv Keller, Xhyljeta Luta, Lucia Mazzolai · 2026 · VASA
  32. Integrative assessment of high-sensitivity C-reactive protein and lipid levels in predicting 20-year atherosclerotic cardiovascular disease risk, in a Mediterranean population: The ATTICA study (2002-2022)
    Sofia‐Panagiota Giannakopoulou, Christina A. Chrysohoou, Smaragdi Antonopoulou, Fotios Barkas, Evangelos N. Liberopoulos, Petros Paul Sfikakis, Christos E. Pitsavos, Costas Tsioufis, Demosthenes B. Panagiotakos · 2026 · American Heart Journal
  33. Non-HDL-cholesterol and residual cardiovascular risk in statin-treated primary-prevention patients
    Jaechan Park, Ju Hyun Kang, Seulggie Choi, Young Jun Park, Changho Han, Sun Jae Park, Hye Jun Kim, Sangwoo Park, Jina Chung, Jiwon Yu et al. · 2026 · European Journal of Preventive Cardiology
  34. Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR), atherogenic index of plasma and acute ischemic stroke classified by CISS
    Zhiwei He, Mengna Lv, Jiaying Luo, Qingwen Li, Zhaohui Zhang, Xuan Niu · 2026 · Frontiers in Neurology
  35. Rethinking Lipid Burden and the Role of Non-LDL Biomarkers in Stroke Risk Stratification
    Sean M. Kelly, Julia Schneider, Michela Rosso, Koto Ishida, Sara Rostanski, Gregory Katz · 2026 · Current Atherosclerosis Reports
  36. The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD
    Xiaoping Li, Lin Yang, Xiao Zhou, Na Ta, Yimeng Zhang, Yanxia Liu · 2026 · Journal of clinical lipidology
  37. Joint assessment of metabolic and functional indices for coronary burden: a real-world study in patients undergoing angiography for chest pain
    Xingxing Che, Mengting An, Wenkai Liu, 郝中建, Ting Gao, Gang Qin · 2026 · Frontiers in Cardiovascular Medicine
  38. Research Progress of Non-HDL-C in Type 2 Diabetes Mellitus Complicated with Cardiovascular Disease
    子琴 谢 · 2026 · Advances in Clinical Medicine
  39. The hidden atherogenic burden of lipoprotein(a): Reclassification by risk-weighted apoB in a multicenter registry
    Pablo Corral, María Gabriela Matta, Sebastián García-Zamora, Natalia Nardelli, Nicolas Federico Renna, Juan Bautista Soumoulou, Santiago Lynch, Federico Salazar, Augusto Lavalle Cobo, LAURA SCHREIER · 2026 · Atherosclerosis
  40. Olezarsen for the treatment of hypertriglyceridemia: A Bayesian reanalysis of randomized controlled trials
    Ana Carolina Covre Coan, Eric Shih Katsuyama, Rodolfo Alves Lopes, Carlos Vergara Sanchez, Alonzo Armani Prata, Christian Ken Fukunaga, A. Talavera, Michael David Shapiro · 2026 · Journal of Pharmacology and Experimental Therapeutics
  41. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management
    Pierre François Sabouret, Dario Mafrica, Domenico Mario Giamundo, Joanna Popiołek-Kalisz, Elad Asher, Dan Atar, Giuseppe Andò · 2026 · Life
  42. Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hypertension in Chinese elderly
    Libin Huang, Shuhong Qin, Fan Qin, Yan Zhang · 2026 · Medicine
  43. Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC/AHA Dyslipidemia Guideline: What Is New and Why It Matters
    Ahmed Kamal Siddiqi, Jerril Jacob, Muhammad Shahzeb Khan, Anandita Kulkarni · 2026 · Current Atherosclerosis Reports
  44. Residual Apolipoprotein B Elevation Despite PREVENT ‐Guided LDL ‐C Goal Attainment Among Adults Without Known ASCVD
    Yanping Shi, Yuan Tang, Mengting Wang, Xu Zhu, Haifeng Zhang · 2026 · Diabetes Obesity and Metabolism
  45. Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment
    Ahmed Talkhan, Mohamed Hamouda Elkasaby, Ahmed S. A. Osman, Muhammad M. Elsharkawy, Mohammad Shehata, kareem ahmed khalefa, Ahmed Mohamed Seleim, Amr M. Abou Elezz, William H. Fishman, Wilbert S. Aronow · 2026 · Cardiology in Review
  46. Association between risk-weighted apolipoprotein B and prevalent kidney stones: a retrospective case-control study
    Xiaogang Chen, Xin Shen, Mengwei Liu, Yi Liu, Qiankun Zhang, Hao Xu, Xiansheng Zhang · 2026 · Frontiers in Medicine
  47. Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers
    Lingling Li, Yixuan Feng, Xiaoya Li, Zongliang Yu, Changxin Sun, Lanqing Hu, Kaidong Zhou, Xinyi Liu, Yongfang Yuan, Liang Li et al. · 2026 · Frontiers in Cardiovascular Medicine
  48. Dyslipidemia in cardio-reno-metabolic syndrome
    David Karásek · 2026 · Vnitřní lékařství
  49. Combined assessment of fibrinogen-to-platelet ratio and ApoB/ApoA1 ratio for pre-angiographic risk stratification of severe multivessel coronary disease in NSTEMI
    Zongqi Zhou, Wei Wang, Haoyu Zhou, Zhiliang Chen, Mingming Jiang, Zimeng Li, Lei Li · 2026 · Frontiers in Cardiovascular Medicine
  50. A Discordant Result of Discordance Analysis—Reply
    Martin Mortensen, Børge Grønne Nordestgaard · 2026 · JAMA Cardiology
  51. Association of the ApoB/ApoA1 Ratio with Angiographically Documented Coronary Artery Disease: Comparison with Conventional Lipid Markers
    Tiberiu Liviu Dragomir, Horia Silviu Branea, Minodora Andor, Ioana Mihaela Citu, Florina Rozina Căruntu, Monica Maria Șușan, Cristina Marinela Oprean, Raul-Tiberiu Dragomir, Răzvan Mihai Șușan, Delia Huțanu et al. · 2026 · Diagnostics
  52. Associations of non-traditional lipid-inflammatory parameters with all-cause mortality in middle-aged and older adults: Insights from two nationally representative cohorts
    Xiaohang Yang, Luna Liu, Xiaoqian Du, Ling Gao, Yue Liu · 2026 · Metabolism Open
  53. Residual risk in coronary artery disease: Identification of cardio–reno–metabolic and psychosocial phenotypes in a Latin American cohort of the INTERASPIRE registry
    Joaquín Perea, Ricardo Alfredo Villarreal, Melisa Elfman, Miguel Urina Triana, Jose Luis Navarro Estrada, Adalberto E. Quintero, Dirk De Bacquer, John William McEvoy, David Wood, Álvaro Sosa Liprandi et al. · 2026 · Current Problems in Cardiology
  54. The cardiovascular risk of metabolically healthy obesity: an inflammatory perspective
    Jimena Lozano-Núñez, Adithya Lakshmi, Binsu Ann Benny, Prashasti Sharma, Anjali Jayakumar, N. L. Swathi · 2026 · Journal of Basic and Clinical Physiology and Pharmacology
  55. Lipid dynamics and cardiovascular risk profiles on carbohydrate- or saturated fat-based diets: secondary analysis of the CARBFUNC trial
    Cathrine Loddervik, Johnny Laupsa‐Borge, Cathrine Horn Sommersten, Kristin Amundsen, Arve Ulvik, Kristine Kjerpeseth Johannessen, Synnøve Halvorsen, Terje Hjalmar Larsen, Ottar Kjell Nygard, Jutta Dierkes et al. · 2026 · EBioMedicine